Moreover, HER2‐positive breast cancer comprises diverse intrinsic subtypes—including HER2‐enriched, basal‐like, Luminal A, and Luminal B—that demonstrate varying degrees of sensitivity to anti‐HER2 therapy [21]. This evidence concerns the gene ERBB2 and breast cancer.